top of page
TOP

海外推奨論文紹介

 この度、国際化推進ワーキンググループの活動の一環として、海外からの論文の中で会員は是非読んでいただきたいと思うものをピックアップし、その論文を簡単にご紹介することを開始致しました。
 

(眼炎症学会国際化推進ワーキンググループ)
委員長 南場研一
委 員 丸山和一、竹内正樹、坪田欣也、松宮 亘、岩橋千春、鈴木佳代

■2023年11月~2024年2月までに発表された論文の中から4報ご紹介いたします。


1. Long-term visual acuity outcomes following cataract surgery in eyes with ocular inflammatory
disease

Gangaputra S, Newcomb C, Armour R, Choi D, Ying GS, Groth S, Begum H, Fitzgerald T,
Artornsombudh P, Daniel E, Bhatt N, Foster S, Jabs D, Levy-Clarke G, Nussenblatt R,
Rosenbaum JT, Sen HN, Suhler E, Thorne J, Dreger K, Buchanich J, Kempen JH; Systemic
Immunosuppressive Therapy for Eye Diseases (SITE) Research Group.
Br J Ophthalmol. 2024 Feb 21;108(3):380-385. doi: 10.1136/bjo-2022-322236.


2. Rising Incidence of Syphilitic Uveitis-Related Hospitalizations in the US
Mir, T. A., Kim, S. J., Fang, W., Harvey, J. & Hinkle, D. M., JAMA ophthalmology 2023 142,
7-14, PMID: 37991790 DOI: :10.1001/jamaophthalmol.2023.53.


3. A large meta-analysis identifies genes associated with anterior uveitis.

Gelfman, S. et al. Nature communications 14, 7300, doi:10.1038/s41467-023-43036-1 (2023).

 

4. Efficacy and Safety of Adalimumab in Patients with Behçet Uveitis: A Systematic Review and Meta-Analysis. Ocular immunology and inflammation

Sener, H., Evereklioglu, C., Horozoglu, F. & Gunay Sener, A. B. 32, 89-97, doi:10.1080/09273948.2022.2157288 (2024). 

 

■2023年7月~2023年10月までに発表された論文の中から5報ご紹介いたします。

1. Risk of Noninfectious Uveitis after Coronavirus Disease 2019 Vaccination in a United States Claims Database. 
Kumar A, Miller DC, Sun Y, Arnold BF, Acharya NR. 
Ophthalmology. 2023 Jul 20:S0161-6420(23)00502-X. 

2. THE HUMIRA IN OCULAR INFLAMMATIONS TAPER (HOT) STUDY.
Pichi F, Smith SD, Goldstein DA, Baddar D, Gerges TKA, Janetos TM, Ruiz-Cruz M, Concha-Del-Río LE, Maruyama K, Carina Ten Berge J, Rombach SM, Cimino L, Bolletta E, Miserocchi E, Scandale P, Serafino M, Camicione P, Androudi S, Gonzalez-Lopez JJ, Lim LL, Singh N, Gupta V, Gupta N, Amer R, Md EMD, Md SI, Munk MR, Donicova E, Carreño E, Takeuchi M, Chee SP, Chew MC, Agarwal A, Schlaen A, Gómez RA, Couto CA, Khairallah M, Neri P.
Am J Ophthalmol. 2023 Sep 19:S0002-9394(23)00377-X. 

3. Non-infectious uveitis risk after Coronavirus Disease 2019 (COVID-19) vaccination: A nationwide retrospective cohort study. 
Chang MS, Kim HR, Kim S, Lee CS, Byeon SH, Kim SS, Lee SW, Kim YJ. 
Am J Ophthalmol. 2023 Sep 20:S0002-9394(23)00381-1.

 

4. Drug-induced uveitis related to Checkpoint inhibitors and MAPkinase inhibitors.
Thibault T, Ben Ghezala I, Freppel R, Rajillah A, Boulay C, Brunel P, Atzenhoffer M, Auvens C, Devilliers H, Grandvuillemin A.
Ophthalmology. 2023 Oct 9:S0161-6420(23)00716-9.

 

5.Comparison of intestinal microbes and metabolites in active VKH versus acute anterior uveitis associated with ankylosing spondylitis.
Li M, Liu M, Wang X, Wei H, Jin S, Liu X.
Br J Ophthalmol. 2023 Oct 11:bjo-2023-324125.

 

 

■2023年3月~2023年6月までに発表された論文の中から5報ご紹介いたします。

1. Navigating Coronavirus Disease 2019 Vaccination and Uveitis: Identifying the Rates and Risk of Recurrent Uveitis after Coronavirus Disease Vaccination
Charlotte A Jordan, Stephanie Townend, Natalie Allen, Joanne Sims, Charles N J McGhee, Rachael L Niederer
Ophthalmology. 2023 May;130(5):501-508. 
doi: 10.1016/j.ophtha.2022.12.013.

2. The role of the retinal nerve fiber layer thickness on OCT in the evaluation of papillitis in childhood uveitis: Evaluating papillitis in pediatric uveitis using OCT-RNFL
Carlyn V Kouwenberg, Laurens A Blom, Suzanne C Vellinga, Irem Bozkir, Joke H de
Boer, Viera Koopman-Kalinina Ayuso
Am J Ophthalmol. 2023 May 4;S0002-9394(23)00199-X.
doi: 10.1016/j.ajo.2023.05.006.

 

3. Intravitreal Therapy for Uveitic Macular Edema-Ranibizumab versus Methotrexate versus the Dexamethasone Implant: The MERIT Trial Results
Multicenter Uveitis Steroid Treatment Trial (MUST) Research Group, Writing Committe:; Nisha R Acharya, Albert T Vitale, Elizabeth A Sugar, Janet T Holbrook, Alyce E Burke, Jennifer E Thorne, Michael M Altaweel, John H Kempen, Douglas A Jabs
Ophthalmology. 2023 May 24;S0161-6420(23)00254-3. 
doi: 10.1016/j.ophtha.2023.04.011. 

4. Usefulness of the QuantiFERON test for the diagnosis of tubercular uveitis and the predictions of response to antituberculosis treatment
Danjou W, Pradat P, Jamilloux Y, Gerfaud-Valentin M, Kodjikian L, Trad S, Seve P.
Br J Ophthalmol. 2023 Apr;107(4):500-504. 
doi: 10.1136/bjophthalmol-2021-318868. Epub 2021 Oct 28.

5. Comparison of Uveitis Incidence by Medication in Juvenile Idiopathic Arthritis and Implications for Screening
Henry S Bison, Timothy M Janetos, Hans M Gao, David L Zhang, Jessica Song, Brenda L Bohnsack
Am J Ophthalmol. 2023 Mar;247:70-78.
doi: 10.1016/j.ajo.2022.11.010.

■2022年11月~2023年2月までに発表された論文の中から5報ご紹介いたします。

1. Antidrug Antibodies to Tumor Necrosis Factor α Inhibitors in Patients With Noninfectious Uveitis

Sunil Bellur , Matthew McHarg, Wijak Kongwattananon , Susan Vitale, H Nida Sen,  Shilpa Kodati.
JAMA Ophthalmol. 2023 Feb 1;141(2):150-156. PMID: 36547953 PMCID: PMC9936342 DOI: 10.1001/jamaophthalmol.2022.5584

2. Alternative Biologic Therapy in Children Failing Conventional TNFα Inhibitors for Refractory, Noninfectious, Chronic Anterior Uveitis.

Virginia Miraldi Utz, Sheila T Angeles-Han, Najima Mwase, Amy Cassedy, Theresa Hennard, Daniel J Lovell, Sarah Lopper, Hermine I Brunner Eniolami O Dosunmu, Alexei A Grom, Michael Henrickson , Jennifer L Huggins, Robert A Sisk, Tracy V Ting, Adam H Kaufman.
Am J Ophthalmol. 2022 Dec;244:183-195. PMID: 35863492 DOI: 10.1016/j.ajo.2022.06.024

 

3.Cataract Surgery in Uveitis: Risk Factors, Outcomes, and Complications

Haya Husam Al-Ani, Joanne Lesley Sims, Rachael Louise Niederer

Am J Ophthalmol. 2022 Dec;244:117-124. DOI:https://doi.org/10.1016/j.ajo.2022.08.014

4. Cerebrospinal Fluid Interleukin-10 Biomarker for Vitreoretinal Lymphoma 

Xiao Zhang, Yan Zhang, Zhe Zhuang, You-Xin Chen, Wei Zhang, Mei-fen Zhang

Am J Ophthalmol. 2023 Feb;246:242-250. DOI:https://doi.org/10.1016/j.ajo.2022.10.009

5. Implications of COVID-19 infection on patients with uveitis under biologic treatment

Abdulrahman F AlBloushi, Abdullah M Alfawaz,  Ahmed M Abu El Asra.

Br J Ophthalmol. 2022 Nov;106(11):1538-1541.  PMID: 33931386 PMCID: PMC8098233 

DOI: 10.1136/bjophthalmol-2020-318577

■2022年7月~2022年11月までに発表された論文の中から5報ご紹介いたします。

1. Long-Term Follow-up of Patients With Uveitis Treated With Adalimumab: Response Rates and Reasons for Discontinuation of Therapy

Laura E M Eurelings, Tom O A R Missotten, Mirjam E J van Velthoven, Paul L A van Daele, Jan A M van Laar, P Martin van Hagen, Alberta A H J Thiadens, Saskia M Rombach
Am J Ophthalmol. 2022 Aug;240:194-204. doi: 10.1016/j.ajo.2022.03.017.

2. Better visual outcome associated with early vitrectomy in the management of endophthalmitis

Sarah Welch, Riyaz Bhikoo, Nancy Wang, Martin J Siemerink, William Shew, Philip J Polkinghorne, Rachael L Niederer

Br J Ophthalmol. 2022 Aug;106(8):1145-1149. doi: 10.1136/bjophthalmol-2020-316846.

 

3.Clinical Course and Outcome in Pediatric Idiopathic Chronic Anterior Uveitis

Carlyn V Kouwenberg, Roos A W Wennink, Mahfam Shahabi, Irem Bozkir, Viera Koopman-Kalinina Ayuso, Joke H de Boer
Am J Ophthalmol. 2022 Sep;241:198-205. doi: 10.1016/j.ajo.2022.04.015.

4. Therapeutic drug monitoring guides the management of patients with chronic non-infectious uveitis treated with adalimumab: a retrospective study 

Lucas Sejournet, Sebastien Kerever, Thibaud Mathis, Laurent Kodjikian, Yvan Jamilloux, Pascal Seve
Br J Ophthalmol. 2022 Oct;106(10):1380-1386. doi: 10.1136/bjophthalmol-2021-319072.

5. Association between Vaccination with the BNT162b2 mRNA Coronavirus Disease 2019 Vaccine and Noninfectious Uveitis: A Population-Based Study.  

Tomkins-Netzer O, Sar S, Barnett-Griness O, Friedman B, Shyriaieva H, Saliba W.
Ophthalmology. 2022 Oct;129(10):1087-1095. doi: 10.1016/j.ophtha.2022.05.015
​.

■2022年3月~2022年6月までに発表された論文の中から4報ご紹介いたします。

1. Lower Relapses Rate With Infliximab Versus Adalimumab in Sight-Threatening Uveitis: A Multicenter Study of 330 Patients.

ぶどう膜炎におけるインフリキシマブとアダリムマブによる再発率の低下:330症例の多施設共同研究

Maalouf G, Andrillon A, Leclercq M, Sève P, Bielefeld P, Gueudry J, Sené T,

Titah C, Moulinet T, Rouvière B, Sène D, Desbois AC, Domont F, Touhami S,

Thibault T, Chamieh CE, Cacoub P, Kodjikian L, Biard L, Bodaghi B, Saadoun D.

Am J Ophthalmol. 2022 Jun;238:173-180. doi: 10.1016/j.ajo.2022.02.002. Epub 2022 Feb 13. 

PMID: 35172172.

 

2. Outcomes of Uveitic Macular Edema in the First-line Antimetabolites as Steroid-Sparing Treatment Uveitis Trial.

Tsui E, Rathinam SR, Gonzales JA, Thundikandy R, Kanakath A, Balamurugan S,

Vedhanayaki R, Lim LL, Suhler EB, Al-Dhibi HA, Doan T, Keenan J, Ebert CD, Kim

E, Madow B, Porco TC, Acharya NR; FAST Research Group. 

Ophthalmology. 2022 Jun;129(6):661-667. doi: 10.1016/j.ophtha.2022.02.002. Epub 2022 Feb 8. 

PMID: 35143800.

 

3.Advanced OCT Analysis of Biopsy-proven Vitreoretinal Lymphoma

Pichi F, Dolz-Marco R, Francis JH, Au A, Davis JL, Fawzi A, Gattousi S,

Goldstein DA, Keane PA, Miserocchi E, Marchese A, Ohno-Matsui K, Sagoo MS, Smith

SD, Sobol EK, Tasiopoulou A, Yang X, Shields CL, Freund KB, Sarraf D.

Am J Ophthalmol. 2022 Jun;238:16-26. doi: 10.1016/j.ajo.2021.11.023. Epub 2021 Nov 27.

PMID: 34843686.

 

4. Anti-Tumor Necrosis Factor α versus Tocilizumab in the Treatment of Refractory Uveitic Macular Edema: A Multicenter Study from the French Uveitis Network. 

Leclercq M, Andrillon A, Maalouf G, Sève P, Bielefeld P, Gueudry J, Sené T, Moulinet T, Rouvière B, Sène D, Desbois AC, Domont F, Touhami S, El Chamieh C, Cacoub P, Bodaghi B, Biard L, Saadoun D. 

Ophthalmology. 2022 May;129(5):520-529. doi: 10.1016/j.ophtha.2021.11.013. Epub 2021 Nov 16. 

PMID: 34793830.

■2021年11月~2022年2月までに発表された論文の中から5報ご紹介いたします。
 
1. Ocular Safety Profile of BRAF and MEK Inhibitors: Data from the World Health Organization Pharmacovigilance Database.
 BRAF、MEK阻害剤の眼に対する安全性:WHO医薬品安全性情報管理データベースを用いた検討
Mettler C, Monnet D, Kramkimel N, et al. Ophthalmology. 2021;128(12):1748-1755


2. Efficacy and safety of oral valganciclovir in cytomegalovirus anterior uveitis with uncontrolled intraocular pressure.
眼圧コントロール不良のサイトメガロウイルス前部ぶどう膜炎に対するバルガンシクロビル内服の有効性と安全性
Wong MOM, Yu AHY, Chan CKM. British Journal of Ophthalmology. 2021;105(12):1666-1671

3. Impact of COVID-19 pandemic on uveitis patients receiving immunomodulatory and biological therapies (COPE STUDY).
COVID-19パンデミックが免疫調整薬や生物学的製剤投与中のぶどう膜炎患者に及ぼす影響について
Aniruddha Kishandutt Agarwal, Sridharan Sudharshan, Padmamalini Mahendradas, Kalpana Babu, Pratik Shenoy, Mohit Dogra, Reema Bansal, Manisha Agarwal, Jyotirmay Biswas, S Balamurugan, Rupesh Agrawal, Vishali Gupta.
British Journal of Ophthalmology. 2022;106(1):97-101

4. Risk of non-infectious uveitis or myasthenia gravis in patients on checkpoint inhibitors in a large healthcare claims database.
大規模な医療費請求データベースにおける免疫チェックポイント阻害剤投与患者の非感染性ぶどう膜炎または重症筋無力症の危険因子
Xia T, Brucker AJ, McGeehan B, VanderBeek BL. Br J Ophthalmol. 2022;106(1):87-90.


5. Efficacy and Safety of Adalimumab and Infliximab for Noninfectious Uveitis.
 非感染性ぶどう膜炎におけるアダリムマブとインフリキシマブの有効性と安全性
Felicia Tai, Parsa Mehraban Far, Petros Pechlivanoglou, Lauren C Ramsay, Jorge R Georgakopoulos,  Beate Sander, Larissa A Derzko-Dzulynsky, Tina Felfeli. Ophthalmology. 2022;129(3):357-359

■2021年7月~2021年10月までに発表された論文の中から6報ご紹介いたします。
 
1.  Intravitreal anti-vascular endothelial growth factor treatment for inflammatory choroidal
neovascularization in non-infectious uveitis.

Woronkowicz M, Niederer R, Lightman S, Tomkins-Netzer O.
Am J Ophthalmol. 2021 Jul 18:S0002-9394(21)00376-7.

2. Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience.
免疫チェックポイン阻害剤の眼副作用:メイヨ―クリニックの経験
Fortes BH, Liou H, Dalvin LA. Br J Ophthalmol. 2021;105(9):1263-1271.

3. Long-term efficacy and tolerability of TNFα inhibitors in the treatment of non-infectious ocular
inflammation: an 8-year prospective surveillance study.

Sharma SM, Damato E, Hinchcliffe AE, Andrews CD, Myint K, Lee R, Dick AD.
Br J Ophthalmol. 2021 Sep;105(9):1256-1262.

4. The association between non-infectious uveitis and COVID-19 outcomes: an analysis of United
States claims-based data.

Miller DC, Sun Y, Chen EM, Arnold BF, Acharya NR.
Ophthalmology. 2021 Oct 11:S0161-6420(21)00751-X.

5. Usefulness of the QuantiFERON test for the diagnosis of tubercular uveitis and the predictions
of response to antituberculosis treatment.

結核性ぶどう膜炎の診断および抗結核療法への治療反応性におけるQuantiFERON 試験の有用
性について
Danjou W, Pradat P, Jamilloux Y, Gerfaud-Valentin M, Kodjikian L, Trad S, Seve P.
Br J Ophthalmol. 2021 Oct 28:bjophthalmol-2021-318868.

6. Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post
Hoc Review of HAWK and HARRIER.

ブロルシズマブにおける炎症、網膜血管炎、ならびに網膜血管閉塞のリスク:第三相試験(HAWK 試験及びHARRIER 試験)
Monés J, Srivastava SK, Jaffe GJ, Tadayoni R, Albini TA, Kaiser PK, Holz FG, Korobelnik JF, Kim IK, Pruente
C, Murray TG, Heier JS.
Ophthalmology. 2021 Jul;128(7):1050-1059.

■2021年1月~2021年6月までに発表された論文の中から5報ご紹介いたします。
 
1.  Development of Classification Criteria for the Uveitides
THE STANDARDIZATION OF UVEITIS NOMENCLATURE (SUN) WORKING GROUP
Am J Ophthalmol. 2021 Apr 20; 228: 96-105.

2. Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis
非感染性の中間部,後部,または汎ぶどう膜炎患者におけるアダリムマブ長期投与時の安全性および有効性について
Eric B Suhler et al, Ophthalmology. 2021 Jun;128(6):899-909.

3. Uveitis in Juvenile Idiopathic Arthritis: 18-Year Outcome in the Population-based Nordic Cohort Study.
若年性特発性関節炎に伴うぶどう膜炎:北欧における集団対象コホート研究による18年間の結果
Rypdal V et al, Ophthalmology. 2021 Jun;128(6):899-909.

4. Recurrence Rates of Inflammation after Switching from the Originator Infliximab to Biosimilar Infliximab-abda for Noninfectious Uveitis
非感染性ぶどう膜炎におけるインフリキシマブからバイオシミラーインフリキシマブに変更後の炎症発作再発率
Deaner JD et al, Am J Ophthalmol. 2021 May; 225: 172-177.

5. Evolving consensus for immunomodulatory therapy in non-infectious uveitis during the COVID-19 pandemic
Agrawal R et al, Br J Ophthalmol. 2021 May;105(5):639-647.

■2020年7月~2021年1月までに発表された論文の中から7報ご紹介いたします。
 
1. Efficacy and Safety of Intravitreal Sirolimus for Noninfectious Uveitis of the Posterior Segment: Results from the Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA) Program.
非感染性後部ぶどう膜炎に対するシロリムス硝子体内投与の有効性と安全性:Sirolimus Study Assessing double-masKed Uveitis tReAtment(SAKURA)の結果
Merrill PT et al, Ophthalmology 127:1405-1415. 2020
2. Effect of a Fluocinolone Acetonide Insert on Recurrence Rates in Noninfectious Intermediate, Posterior, or Panuveitis: Three-Year Results.
フルオシノロンインサートの非感染性ぶどう膜炎再発率に対する効果-3年間の結果
Jaffe GJ et al, Ophthalmology 127:1395-1404. 2020
3. Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis: Phase 3 Randomized Trial.
非感染性ブドウ膜炎に続発する黄斑浮腫に対する上脈絡膜腔CLS-TAの有効性と安全性:第3相ランダム化試験。PEACHTREE Study
Yeh S et al, Ophthalmology 127:948-955. 2020
4. Role of Prophylactic Vitrectomy in Acute Retinal Necrosis in Preventing Rhegmatogenous Retinal Detachment: Systematic Review and Meta-analysis.
急性網膜壊死による裂孔原性網膜剥離の予防における予防的硝子体切除術の役割:システマティックレビューおよびメタアナリシス
Fan S et al, Ocul Immunol Inflamm. Sep 23:1-5. Epub ahead of print. 2020
5. Identifying RNA Biomarkers and Molecular Pathways Involved in Multiple Subtypes of Uveitis.
様々なぶどう膜炎に関与しているRNAバイオマーカーと分子パスウエイの同定Rosenbaum JT et al, Am J Ophthalmol. Jan 24 Epub ahead of print. 2021
6. Seven-Year Outcomes of Uveitic Macular Edema: The Multicenter Uveitis Steroid Treatment Trial and Follow-up Study Results.
ぶどう膜炎における黄斑浮腫の長期成績(7年間): 多施設ぶどう膜炎ステロイド治療試験(MUST)と追跡調査結果
Tomkins-Netzer O et al, Ophthalmology. Sep 10. Epub ahead of print. 2020
7. Monthly Intravitreal Infliximab in Behçet's Disease Active Posterior Uveitis: A Long-Term Safety Study.
活動性後眼部ぶどう膜炎を有するベーチェット病における毎月のインフリキシマブ硝子体内注射―長期安全性試験−
Refaat M et al, Retina. Dec 28 Publish Ahead of Print. 2020

bottom of page